GlassScriptPhysician profile
Tyrus S Soares
NPI 1154348191
$8,417.58
in general payments reported to CMS, 2019-2025
33 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $746 · 2021: $1,069 · 2022: $3,109 · 2023: $623 · 2024: $1,404 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133 · Travel and Lodging: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.59 |
| Travel and Lodging | $553.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,156.91 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Abbott Laboratories | $679.31 | 2019-2024 | Eterna |
| Stryker Corporation | $280.21 | 2021-2023 | Ortholoc 2 Lapifuse |
| Boston Scientific Corporation | $256.35 | 2019-2025 | General - Pain Management, Patient Trial Kit, Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.42 | 2020-2023 | Relistor |
| Collegium Pharmaceutical, INC. | $185.93 | 2021-2025 | Belbuca, Xtampza |
| Vertex Pharmaceuticals Incorporated | $182.62 | 2024-2025 | |
| Medtronic USA, INC. | $180.39 | 2019-2020 | |
| Nevro Corp. | $157.25 | 2019-2021 | |
| Forte Bio-Pharma LLC | $112.60 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $98.44 | 2019-2020 | |
| Si-Bone, INC. | $97.56 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $96.79 | 2021 | |
| Lundbeck LLC | $90.04 | 2020 | |
| Pfizer INC. | $71.07 | 2020-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $63.92 | 2020-2021 | |
| Tonix Medicines, INC. | $54.90 | 2025 | Tonmya |
| Abbvie INC. | $54.76 | 2021-2025 | |
| Biodelivery Sciences International, INC. | $52.57 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $52.22 | 2023-2024 | Horizant, Horizant |
| Lilly USA, LLC | $40.27 | 2019-2020 | |
| Averitas Pharma INC. | $38.81 | 2023-2025 | Qutenza |
| Biotronik Nro, INC. | $33.86 | 2025 | Prospera |
| Grt US Holding, INC. | $32.15 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.12 | 2019-2020 | |
| Gilead Sciences, INC. | $24.60 | 2020 | |
| Sentynl Therapeutics, INC. | $22.52 | 2019 | |
| Protega Pharmaceutials INC | $19.43 | 2025 | Roxybond |
| Amag Pharmaceuticals, INC. | $18.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.83 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.87 | 2019 | |
| Myriad Genetic Laboratories, INC. | $11.91 | 2021 | |
| Spr Therapeutics, INC | $6.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyrus Soares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.